Articles

Lilly halts development of Alzheimer’s drug

Studies showed that the treatment did not slow the disease's progression. It's just the latest setback for the pharmaceutical
giant, which lost a patent lawsuit over a major drug last week and faces an unprecedented number of patent expirations through
2014.

Read More

Positron has billion-dollar hopes for medical-imaging scanner

A maker of medical imaging equipment that recently moved its headquarters to Fishers has grand plans to reach $1 billion in
sales and build a multimillion-dollar cyclotron facility in five years. But history shows Positron Corp. has been far better
at losing money than making it.

Read More

Lilly still waiting on once-weekly Byetta

The U.S. Food and Drug Administration last week pushed its self-declared deadline for rendering an approval decision on the
drug Bydureon to Oct. 22. The previous deadline was in March.

Read More

New federal funds come with big goals

Indiana has now received nearly $50 million in federal bucks to digitize health care around the state. But the latest grant—$16
million to the Indiana Health Information Exchange—comes with specific, ambitious goals for health care providers.

Read More

Lilly: Alimta improves lung-cancer survival time

Indianapolis-based Eli Lilly and Co. announced today that a clinical trial showed lung cancer patients treated with Lilly
drug Alimta lived about three months longer than those who received the best available care.

Read More